Connect with us

Hi, what are you looking for?

Jewish Business News

StartUps

Hello Heart App Proven to Reduce Blood Pressure

Hello Heart

Michal Gutman (from right) CTO & CISO, Maayan Cohen, Co-Founder and CEO, and Ziv Meltzer, Co-Founder, Chief Design. Photo Hello Heart

Hello Heart is an Israeli medtech startup offering a digital program that helps users to understand and improve their heart health. Heart conditions are the number one cost factor for employers. The Hello Heart program is clinically based and targets people with high blood pressure. Now a JAMA study of over 28,000 participants found that 84% of Hello Heart users successfully reduced their blood pressure.

Launched in 2013, the digital therapeutic company’s app helps patients manage their blood pressure, pulse, medications and physical activity using artificial intelligence.

Every participant receives a wireless blood pressure monitor and real-time personalized tips on their smartphone. The solution, says the company, helps participants improve their heart health in a fun and engaging way. Hello Heart delivers real results – enrollment rates are 45% of targeted employees, and 70% of participants at risk reduce their blood pressure using Hello Heart.
999
“When my partner was diagnosed with a serious disease I found myself in the patient’s seat. I started tracking vital signs, collecting medical records and spending hours online trying to understand it. I realized that as patients, we don’t have tools to understand and improve our health. It’s time to change that,” Maayan Cohen, Hello Heart CEO.

According to a study published in the JAMA Network Open, a peer-reviewed Journal of the American Medical Association, the Hello Heart digital health application for blood pressure management can achieve and maintain lower blood pressure over time, even for those most at risk for heart disease. The results showed that over 84 percent of participants with stage II hypertension achieved a reduction in their systolic blood pressure, which was maintained over three years. This research is the largest multi-year study of the efficacy of a digital therapeutic in controlling hypertension.

“There is a high amount of skepticism and cynicism around hypertension management solutions because for years, there has been no effective solution, and current solutions yield low participant engagement. We’re pleased that the study demonstrated such strong clinical results that are sustained over three years for Hello Heart users,” said Maayan Cohen, CEO of Hello Heart. “It can be very uncomfortable and even scary for companies to subject their findings to a peer review. We have been helping users with their cardiac health for several years and are proud to put our clinical results through a peer-review process that validates what we already know—Hello Heart has strong, sustained clinical impact, at scale.”

This past May, Hello Heart brought in $45 million in a Series C round was led by IVP, to build out its technology

“Hypertension is the most prevalent chronic condition in America, impacting roughly half the U.S. population,” Parsa Saljoughian, partner at IVP, said in a press release.

Click to comment

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement